Clinical Trial Update: HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial update of HAIC combined with sintilimab and a bevacizumab biosimilar in unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• HAIC (hepatic artery infusion chemotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN